老虎证券

BRIEF-Zai Lab Receives U.S. FDA Fast Track Designation For Zl-1310, A Dll3-Targeted Antibody-Drug Conjugate, For Treatment Of Extensive-Stage Small Cell Lung Cancer

Reuters
2025/05/19
BRIEF-Zai Lab Receives U.S. FDA Fast Track Designation For Zl-1310, A Dll3-Targeted Antibody-Drug Conjugate, For Treatment Of Extensive-Stage Small Cell Lung Cancer

May 19 (Reuters) - Zai Lab Ltd 9688.HK:

  • ZAI LAB RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR ZL-1310, A DLL3-TARGETED ANTIBODY-DRUG CONJUGATE, FOR TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

  • ZAI LAB LTD - TO INITIATE PIVOTAL STUDY FOR ZL-1310 IN 2025

Source text: ID:nBw5PTTCha

Further company coverage: 9688.HK

((Reuters.Briefs@thomsonreuters.com;))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10